EP
NRIX icon

Essential Partners’s Nurix Therapeutics NRIX Stock Holding History

Essential Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.61K Buy
190
+83
+78% +$1.41K ﹤0.01% 1579
2026
Q1 		$1.66K Buy
+107
New +$1.77K ﹤0.01% 2075

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's NRIX Position: Q2 2026 in Review

Essential Partners increased its Nurix Therapeutics (NRIX) stake by 78% in Q2 2026, buying an estimated $1.41K and bringing the position to 190 shares worth $4.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Essential Partners first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Essential Partners held 190 shares of Nurix Therapeutics worth $4.61K as of Q2 2026.
  • Essential Partners bought 83 Nurix Therapeutics shares in Q2 2026, an estimated $1.41K.
  • Nurix Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1579 holding.
  • Essential Partners first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.